Skip to main content

Table 3 Base case clinical results: incremental life years per 1,000 patients

From: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Cohort Evaluated Incremental Life Years
PMO Patients (100% Female), age 69 years, T-Score = −3.0  
historical vertebral + incident vertebral fracture  
 Teriparatide vs. No Treatment 132
 Teriparatide vs. bisphosphonate 102
incident vertebral fracture  
 Teriparatide vs. No Treatment 102
 Teriparatide vs. bisphosphonate 77
GIOP Patients (80% Female), age 69 years, T-Score = −2.5  
historical vertebral + incident vertebral fracture  
 Teriparatide vs. No Treatment 153
 Teriparatide vs. bisphosphonate 117
incident vertebral fracture  
 Teriparatide vs. No Treatment 140
 Teriparatide vs. bisphosphonate 106